info@seagull-health.com
SeagullHealth
语言:
search
new
How to Purchase Repotrectinib (Augtyro)
502
Article source: Seagull Pharmacy
Nov 13, 2025

Repotrectinib (Augtyro) is a next-generation kinase inhibitor and an important targeted medication for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) and NTRK gene fusion-positive solid tumors.

How to Purchase Repotrectinib (Augtyro)

Overseas Purchase

Patients may choose to consult and purchase repotrectinib at hospital pharmacies or authorized retail pharmacies in countries or regions where the medication has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase via Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Repotrectinib (Augtyro)

Defined Indication Scope

Locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in adults.

NTRK gene fusion-positive solid tumors in adult and pediatric patients aged 12 years and older.

Patient Screening Requirements

NSCLC patients must undergo testing for ROS1 rearrangement in tumor specimens.

Solid tumor patients must undergo testing for NTRK1/2/3 rearrangements.

For patients with secretory breast carcinoma or breast cancer-like secretory carcinoma, treatment may be considered without confirming NTRK rearrangement.

Important Pre-Treatment Examinations

Liver function tests (including bilirubin).

Uric acid level testing.

Medications Prohibited for Concomitant Use

Strong and moderate CYP3A inhibitors.

P-gp inhibitors.

Strong and moderate CYP3A inducers.

Certain CYP3A substrates.

Hormonal contraceptives.

Key Methods to Identify the Authenticity of Repotrectinib (Augtyro)

Verify Packaging Characteristics

40 mg strength: Available in bottles of 60 capsules or 120 capsules.

160 mg strength: Available in bottles of 14 capsules or 60 capsules.

Carefully verify the accuracy of the drug approval number and manufacturer information.

Confirm Capsule Markings

40 mg capsules: White opaque, Size 0 hard-shell capsules. The contents are white to off-white powder, which may be in the form of a plug. The cap is printed with blue text "REP40".

160 mg capsules: Blue opaque, Size 0 hard-shell capsules. The contents are white to off-white powder, which may be in the form of a plug. The cap is printed with white text "REP160".

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
What Are the Side Effects of Rasagiline (Azilect)?
Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor, approved for the treatment of Parkinson's disease. While this medication effectively improves motor...
Precautions for Using Rasagiline (Azilect)
Rasagiline (Azilect) is one of the important medications currently used for the treatment of Parkinson's disease. As a monoamine oxidase (MAO) inhibitor, this drug carries specific risks such as h...
How to Use Rasagiline (Azilect)
Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor, which was first approved for marketing in the United States in 2006. This medication is indicated for t...
Indications for Rasagiline (Azilect)
Rasagiline (Azilect) is a selective and irreversible monoamine oxidase type B (MAO-B) inhibitor. Since its approval by the U.S. FDA in 2006, it has become an important treatment option for Parkinson&#...
Indications for Repotrectinib (Augtyro)
Repotrectinib (Augtyro) is an innovative kinase inhibitor that received its first approval from the U.S. Food and Drug Administration (FDA) in 2023. As a next-generation targeted therapy, repotrectini...
How to Use Repotrectinib (Augtyro)
Repotrectinib (Augtyro) is a novel kinase inhibitor that received its first approval in the United States in 2023. This medication is primarily indicated for the treatment of ROS1-positive non-small c...
Indications for Vigabatrin (Sabril)
Vigabatrin (Sabril) is an antiepileptic drug commonly used to treat specific types of seizures, particularly in cases where other treatments have shown poor efficacy. Understanding its indications, do...
How to Purchase Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia)
Teneligliptin Hydrobromide/Canagliflozin Combination Tablets (Canalia) is a dual-target (DPP-4 and SGLT2) fixed-dose combination preparation developed by Mitsubishi Tanabe Pharma (Japan). It demonstra...
Related Articles
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
Adverse Reactions of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...
What Are the Precautions for Using Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...
Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...
What Are the Indications for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...
What Are the Purchase Channels for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved